Vitamin D Protects Against Atherosclerosis via Regulation of Cholesterol Efflux and Macrophage Polarization in Hypercholesterolemic Swine

Kai Yin, Yong You, Vicki Swier, Lin Tang, Mohamed M. Radwan, Amit N. Pandya, Devendra K. Agrawal

Objective—Prevalence of vitamin D (VD) deficiency and its association with the risk of cardiovascular disease prompted us to evaluate the effect of VD status on lipid metabolism and atherosclerosis in hypercholesterolemic microswine.

Approach and Results—Yucatan microswine were fed with VD-deficient (0 IU/d), VD-sufficient (1000 IU/d), or VD-supplemented (3000 IU/d) high-cholesterol diet for 48 weeks. Serum lipids and 25(OH)-cholecalciferol levels were measured biweekly. Histology and biochemical parameters of liver and arteries were analyzed. Effect of 1,25(OH)2D3 on cholesterol metabolism was examined in human hepatocyte carcinoma cell line (HepG2) and human monocyte cell line (THP-1) macrophage-derived foam cells. VD deficiency decreased plasma high-density lipoprotein levels, expression of liver X receptors, ATP-binding membrane cassette transporter A1, and ATP-binding membrane cassette transporter G1 and promoted macrophage accumulation and atherosclerosis in hypercholesterolemic microswine. VD promoted nascent high-density lipoprotein formation in HepG2 cells via ATP-binding membrane cassette transporter A1–mediated cholesterol efflux. Cytochrome P450 (CYP)27B1 and VD receptor were predominantly present in the CD206+ M2 macrophage foam cell–accumulated cores in coronary artery plaques. 1,25(OH)2D3 increased the expression of liver X receptors, ATP-binding membrane cassette transporter A1, and ATP-binding membrane cassette transporter G1 and promoted cholesterol efflux in THP-1 macrophage–derived foam cells. 1,25(OH)2D3 decreased intracellular free cholesterol and polarized macrophages to M2 phenotype with decreased expression of tumor necrosis factor-α, interleukin-1β, interleukin-6 under lipopolysaccharide stimulation. 1,25(OH)2D3 markedly induced CYP27A1 expression via a VD receptor–dependent c-Jun N-terminal kinase (JNK) 1/2 signaling pathway and increased 27-hydroxycholesterol levels, which induced liver X receptors, ATP-binding membrane cassette transporter A1, and ATP-binding membrane cassette transporter G1 expression and stimulated cholesterol efflux that was inhibited by VD receptor antagonist and JNK1/2 signaling inhibitor in THP-1 macrophage–derived foam cell.

Conclusions—VD protects against atherosclerosis in hypercholesterolemic swine via controlling cholesterol efflux and macrophage polarization via increased CYP27A1 activation. (Arterioscler Thromb Vasc Biol. 2015;35:2432-2442. DOI: 10.1161/ATVBAHA.115.306132.)

Key Words: atherosclerosis ◼ cardiovascular disease ◼ cholesterol efflux ◼ hydroxycholesterols ◼ macrophage polarization ◼ vitamin D
functionally distinct phenotypes that are usually characterized by the classical proinflammatory M1 macrophages and alternatively activated anti-inflammatory M2 macrophages. Several ligand-activated nuclear hormone receptors, such as liver X receptor-α (LXR-α) and peroxisome proliferator-activated receptor-γ, are important lipid sensors that not only regulate expression of genes involved in lipid metabolism but also regulate macrophage polarization.

Vitamin D (VD) deficiency has been rising in the general population. Approximately 50% of the population worldwide has low levels of plasma 25-hydroxyvitamin D (25(OH)D, <20 ng/mL), a stable marker of VD status. Beyond its well-defined role in calcium homeostasis, VD has recently been identified as an important factor in cardiovascular health. Clinical studies have indicated that plasma 25(OH)D, level below 20 ng/mL is associated with increased risk for coronary heart disease. Several mechanisms, including protection of endothelial function, modulation of immune response, inhibition of vascular smooth muscle cell growth, have been proposed to account for the antiatherosclerotic effect of VD. Recently, several large retrospective studies demonstrated that VD deficiency is associated with atherogenic lipid profile, including increased serum LDL and decreased HDL levels. High 25(OH)D, concentrations in the elderly are associated with low prevalence of metabolic syndrome with more beneficial HDL cholesterol (HDL-C) levels. 1,25(OH)D, the biologically active form of VD, suppresses foam cell formation by reducing oxidized LDL uptake in diabetic subjects. However, repletion of 25-hydroxyvitamin D levels in the short term has not improved the lipid profile in human. Thus, further studies are warranted to define the exact role of VD on the lipid metabolism and atherosclerosis.

In the present study, we found that VD deficiency decreased plasma HDL levels and promoted the progression of atherosclerosis in hypercholesterolemic swine via impaired LXRs/ABCA1 pathway, a crucial regulator in the formation and function of HDL. Our experiments revealed that 1,25(OH)D, promotes nascent HDL formation in human hepatocyte carcinoma cell line (HepG2) cells via ABCA1-mediated cholesterol efflux. In human monocytic cell line (THP-1) macrophages–derived foam cell, 1,25(OH)D, increased the expression of LXRs, ABCA1, and ATP-binding membrane cassette transporter G1 (ABCG1) and promoted cholesterol efflux and polarized macrophages to an M2 phenotype with decreased expression of inflammatory cytokines under lipopolysaccharide stimulation. 1,25(OH)D, causes upregulation of cytochromes P450 (CYP)27A1 via a VD receptor (VDR)–dependent c-Jun N-terminal kinase (JNK) 1/2 signaling, which plays a crucial role in the activation of LXRs/ABCA1/ABCG1 pathway.

Materials and Methods

Materials and methods are available in the online-only Data Supplement.

Results

VD Deficiency Decreases Plasma HDL Level and Promotes Atherosclerosis in Hypercholesterolemic Swine

To investigate the effect of VD on the lipid metabolism and the progression of atherosclerosis, microswine were fed on VD-deficient (VD Def), VD-sufficient (VD Suf), and VD-supplemented (VD Sup) high-cholesterol diets. As shown in Figure 1A, VD Def diet produced significant VD deficiency, whereas VD Sup diet increased the serum level of 25(OH)D, a stable marker of VD status. Lipid levels of animals fed with high-cholesterol diets were increased with time. Compared with VD Suf group, a significant decrease in HDL-C was observed as early as the end of the third month in VD Def group (VD Def group, 68.4±7.9 mg/dL; VD Suf group, 87.8±6.2 mg/dL; VD Sup group, 98.5±10.3 mg/dL; P<0.01). Furthermore, the VD Sup group had significantly higher level of HDL-C at month 12 compared with the VD Suf group (VD Suf group, 98.3±9.6 mg/dL; VD Sup group, 117.3±12.8 mg/dL; VD Suf group, 117.3±12.8 mg/dL; P<0.05; Figure 1B). Compared with VD Suf group, VD deficiency increased while VD supplementation decreased the levels of LDL cholesterol. Nevertheless, there was no statistically significant difference among these groups (Figure 1B).

To investigate the effect of VD status on the atheroma progression in hypercholesterolemic swine, the histological analyses of fatty streak in thoracic aorta from different treatment groups were compared. As shown in Figure 1C, relative aortic fatty streak lesion area was 49.35±6.17% for the VD Def group, 34.11±2.56% for the VD Suf group, and 24.28±3.05% for the VD Sup group (P<0.01; Figure 1B). Compared with VD Suf or VD Sup; P<0.05, VD Sup compared with VD Suf), suggesting that VD deficiency resulted in a more remarkable progress in aortic fatty streak lesions formation under high-cholesterol diet. To further evaluate the extent of atherosclerosis, common carotid arteries from 3 dietary groups were analyzed for total cholesterol and cholesteryl ester deposition (Figure 1D). Total cholesterol contents of the arteries were significantly higher in the swine from VD Def group than in swine from the VD Suf or VD Sup group (P<0.01, 58.9±9.81 versus 36.8±5.28 μmol/g artery or 58.9±9.81 versus 35.5±4.44 μmol/g artery). Free cholesterol content in the common carotid artery was significantly increased by 73.2% or 93.2% in the VD Def group compared with VD Suf or VD Sup groups, respectively, further suggesting that VD deficiency exacerbates the lipid accumulation and atherosclerosis in hypercholesterolemic microswine.

Nonstandard Abbreviations and Acronyms

ABCA1 ATP-binding membrane cassette transporter A1
ABCG1 ATP-binding membrane cassette transporter G1
CYP cytochrome P450
HDL high-density lipoprotein
HOC hydroxysterol
LDL low-density lipoprotein
LXR liver X receptor
VD vitamin D
VD Def vitamin D–deficient
VD Sup vitamin D–supplemented
VD Deficiency Decreases 27-Hydroxycholesterol Level in Liver of Hypercholesterolemic Swine

To examine the molecular signaling targets that could explain the difference in HDL levels response to VD status, we first performed microarray analysis to examine differentially expressed genes in liver, which is the major organ for the synthesis of HDL. A total of 24,124 genes were examined using the porcine GeneChip for liver of pigs (n=4 for each treatment groups). A total of 342 mRNAs were identified as being up- or downregulated >2-fold in the VD Def group compared with VD Suf and VD Sup groups. Of these genes, 38 genes were regulated in a VD dose-dependent manner. Analysis of these genes using Gene Ontology Biological Process revealed that differential expression of genes primarily regulates the following biological functions: oxidative stress, lipid metabolism and inflammatory response, and cell signaling and interactions (Table I in the online-only Data Supplement). These results support the concept that in addition to its established role in regulating calcium homeostasis, VD seems to play an important role in the modulation of metabolic inflammatory diseases, including atherosclerosis. Prominent effects of VD on the genes in the lipid metabolism were noted. Interestingly, the transcription of genes encoding oxysterol receptor LXR pathway, ligand-activated transcription factors that raise HDL-C levels, was significantly decreased in the VD Def group (Table I in the online-only Data Supplement and Figure 2A). After further validation by Western blot, the key proteins in the LXR pathway, including LXR-α and LXR-β, its target gene ABCA1, and steroid catabolic gene CYP27A1 were decreased in VD Def group compared with VD Suf and VD Sup groups (Figure 2B). CYP27A1 plays a crucial role in the biogenesis of oxysterols, crucial ligands for the activation of LXRs. To clarify whether the regulated effect of VD on the HDL metabolism is related to the oxysterol metabolism, the levels of steroid catabolic intermediates, including 27-hydroxycholesterol (HOC), desmosterol, and 24,25-epoxycholesterol, in the liver were measured in the 3 groups. Compared with VD Suf and VD Sup groups, VD deficiency decreased the levels of 27-HOC. However, there was no significant difference in the levels of desmosterol and 24,25-epoxycholesterol in the 3 groups. Compared with VD Suf and VD Sup groups, VD deficiency decreased the levels of 27-HOC. However, there was no significant difference in the levels of desmosterol and 24,25-epoxycholesterol in the 3 groups (Figure 2C). In the cultured HepG2 cell, 1,25(OH)2D3 (10 nM) treatment substantially upregulated the expression of CYP27A1 in a time-dependent manner (Figure 2D) and increased 27-HOC concentrations in oxidized LDL-loaded HepG2 cells (Figure 2E). The activation of LXRs by oxysterol ligands induces the expression of ABCA1, which interacts with apolipoprotein A-I (apoA-I) and promotes the cholesterol efflux that plays a crucial role in the biogenesis of nascent HDL.

Because 1,25(OH)2D3 increases 27-HOC production in HepG2 cells, we investigated whether 1,25(OH)2D3 plays a role in nascent HDL formation. After labeling overnight with [1,2-3H(N)]cholesterol, HepG2 cells were treated with LXR agonist T0901317 (5 μM),...
27-HOC (1 μM), and 1,25(OH)2D3 (10 nM), respectively, for 18 h and then incubated with lipid-free apoA-I (25 μg/mL) for 12 h. The medium was collected and filtered through a 0.45 μm polyvinylidene fluoride membrane to separate non-HDL and HDL. The radioactivity in [3H]-HDL fraction was determined by liquid scintillation counter. We found that the 1,25(OH)2D3 and the LXR agonist T0901317 and 27-HOC significantly increased cholesterol efflux to apoA-I (Figure 2F). After the incubation, ABCA1 protein expression in HepG2 cells was markedly increased by T0901317, 27-HOC, and 1,25(OH)2D3 (Figure 2G). Overall, these data suggest that 1,25(OH)2D3 promotes the nascent HDL formation in HepG2 cells by upregulating CYP27A1 activity and ABCA1 expression.

VD Increases Cholesterol Efflux and M2 Polarization in Coronary Artery of Hypercholesterolemic Swine

To determine the exact mechanism of VD on the inhibition of atherosclerotic progress, we stained coronary plaques from hypercholesterolemic swine. As shown in Figure 3A, VD metabolism, signal-related proteins, including CYP27B1, and VDR were predominantly present in the macrophage foam cell–accumulated cores of plaques in coronary artery. Vitamin D3 and its biologically active form, 1,25(OH)2D3, have been confirmed to have crucial effects on macrophage function via binding to its receptor VDR. Therefore, this data suggest that VD-mediated inhibition of atherosclerosis may be the result from the direct effect of VD on arterial wall, besides its effect on HDL levels. Macrophages, with extreme polarization phenotypes M1 and M2 macrophages, are the major cell components in atherosclerotic lesion that contribute to the foam cell formation and secretion of inflammatory factors. To clarify the exact role of VD in macrophage function, we compared the staining intensity between M1 marker CCR7 and M2 marker mannose receptor (CD206) in the regions of CYP27B1-positive and VDR-positive cores in plaques. We found significantly greater staining of M2 macrophage marker, CD206, in VDR-positive area, whereas proinflammatory M1
macrophage marker CCR7 showed minimal immunoreactivity in this area (Figure 3A), suggesting that VD may play a role in the regulation of macrophage differentiation and inflammatory response in atherosclerotic lesion. To verify this hypothesis, we examined the expression of proinflammatory cytokines (tumor necrosis factor (TNF)-α and interleukin (IL)-1β) by ELISA. C, ATP-binding membrane cassette transporter A1 (ABCA1)/ATP-binding membrane cassette transporter G1 (ABCG1) are coexpressed with VDR at sites of M2 macrophage foam cells in coronary atherosclerotic lesions of hypercholesterolemic swine. D, Western blot analysis of ABCA1, ABCG1, liver X receptors (LXR)-α, and LXRβ expression in the common carotid arteries of different hypercholesterolemic swine. Values are means±SEM for n=3 animals per group. Statistical differences between groups were detected by 1-way ANOVA (*P<0.05, vitamin D–deficient [VD Def] compared with vitamin D–sufficient [VD Suf] or vitamin D–supplemented [VD Sup]; #P<0.05, VD Sup or VD Suf, n=3).

Figure 3. Vitamin D increases cholesterol efflux and M2 macrophage polarization in artery of hypercholesterolemic swine. A, Vitamin D signal-related CYP27B1 and vitamin D receptor (VDR) are expressed at sites of M2 macrophage (CD206 positive) foam cells in coronary atherosclerotic lesions of hypercholesterolemic swine (Left, Movat stain; Right, Immunohistochemistry). B, Proteins from the common carotid arteries of different treatment groups of swine were isolated and analyzed to determine the levels of inflammatory cytokines tumor necrosis factor (TNF)-α and interleukin (IL)-1β by ELISA. C, ATP-binding membrane cassette transporter A1 (ABCA1)/ATP-binding membrane cassette transporter G1 (ABCG1) are coexpressed with VDR at sites of M2 macrophage foam cells in coronary atherosclerotic lesions of hypercholesterolemic swine. D, Western blot analysis of ABCA1, ABCG1, liver X receptors (LXR)-α, and LXRβ expression in the common carotid arteries of different hypercholesterolemic swine. Values are means±SEM for n=3 animals per group. Statistical differences between groups were detected by 1-way ANOVA (*P<0.05, vitamin D–deficient [VD Def] compared with vitamin D–sufficient [VD Suf] or vitamin D–supplemented [VD Sup]; #P<0.05, VD Sup or VD Suf, n=3).

1,25(OH)2D3 Promotes Cholesterol Efflux and M2 Polarization in Macrophage-Derived Foam Cells via Upregulating 27-HOC

To further determine whether 1,25(OH)2D3 altered cholesterol efflux in macrophages, we analyzed the effect of 1,25(OH)2D3 on ABCA1-mediated cholesterol efflux in THP-1 macrophage–derived foam cells. As shown in Figure 4A, oxidized LDL-induced macrophage-derived foam cells cultured in 1,25(OH)2D3-deficient media exhibited a significantly greater staining in oil red after treatment.
with apoA-I compared with macrophage-derived foam cells cultured in 1,25(OH)₂D₃-supplemented media. Next, we examined the effect of 1,25(OH)₂D₃ on cholesterol content and cholesterol efflux in THP-1 macrophage-derived foam cells. As shown in Figure 4B and 4C, the ability of apoA-I to decrease cholesterol content and to promote cholesterol efflux in THP-1 macrophage-derived foam cell was significantly increased in 1,25(OH)₂D₃-supplemented media compared with 1,25(OH)₂D₃-deficient media. To determine whether the increased ability of apoA-I to promote cholesterol efflux in 1,25(OH)₂D₃-supplemented media is related to cholesterol transporters, we analyzed the expression of ABCA1 and ABCG1 in these cells. Analysis of protein levels by Western blotting demonstrated a 1,25(OH)₂D₃-induced upregulation in the levels of ABCA1 and ABCG1 expression in THP-1 macrophage-derived foam cells (Figure 4D).

Macrophages-derived foam cells from atherosclerotic subjects have been shown to exhibit classic (M1) proinflammatory phenotype.⁵ LXR-α activation and increasing ABCA1 levels have been found to inhibit inflammation and induce expression of IL-10, a marker of the M2 macrophage phenotype.¹⁸ To investigate whether the increased activation of LXR-α induced by 1,25(OH)₂D₃ results in the macrophage phenotypic polarization, we compared the expression of M1 or M2 marker in basal, IL-4, or lipopolysaccharide condition. Compared with 1,25(OH)₂D₃-deficient media, the macrophages from 1,25(OH)₂D₃-supplemented media have a significant increase in IL-4-stimulated mRNA expression of CD206 and MGL-1 (Figure 4E). Cells were analyzed by fluorescence-activated cell sorter using anti-mannose receptor CD206 antibody. As shown in Figure 4F, 1,25(OH)₂D₃ robustly increased IL-4-induced expression of CD206, suggesting 1,25(OH)₂D₃

---

**Figure 4.** 1,25(OH)₂D₃ promotes cholesterol efflux and M2 polarization in macrophage-derived foam cells via upregulating 27-hydroxycholesterol (HOC). A, Human monocytic cell line (THP-1) macrophages were treated with oxidized high-density lipoprotein (oxLDL; 50 μg/mL) for 48 h, then cultured with apolipoprotein A-I (apoA-I; 25 μg/mL) under 1,25(OH)₂D₃-deficient medium (top) or 1,25(OH)₂D₃ (10 nM)-supplemented medium (bottom) for 24 h. Macrophages were stained with Oil Red O. B, The intercellular free cholesterol (FC) was determined by the cholesterol quantification kit. n=3; ***P<0.001, **P<0.01, *P<0.05, 2-way analysis of variance (ANOVA) with Bonferroni’s post hoc test. C, Liquid scintillation counting was performed to determine the intercellular cholesterol efflux. D, THP-1 macrophage-derived foam cells were treated with 1,25(OH)₂D₃ (10 nM) for 0, 6, 12, and 24, and the expression of ABCA1 and ABCG1 were determined by Western blot. E, After cultured with 1,25(OH)₂D₃ (10 nM) for 24 h, THP-1 macrophage-derived foam cells were treated with interleukin (IL)-4 (20 ng/mL) for 6 h. The M2 marker (CD206 and MGL-1) mRNA levels in cells were determined by quantitative real-time polymerase chain reaction. F, Representative histograms of CD206/mannose receptor (MR) in THP-1 macrophage-derived foam cells exposed to vehicle (Ctrl), 1,25(OH)₂D₃ (10 nM), IL-4 (20 ng/mL), or IL-4+1,25(OH)₂D₃. G, After cultured with 1,25(OH)₂D₃ (10 nM) for 24 h, THP-1 macrophage-derived foam cells were treated with lipopolysaccharide (LPS; 10 ng/mL) for 12 h. The level of tumor necrosis factor (TNF)-α was quantified by ELISA. n=3; **P<0.01, *P<0.05, 2-way analysis of variance (ANOVA) with Bonferroni’s post hoc test. H, THP-1 macrophage-derived foam cells were treated with either vehicle (ethanol) or 1,25(OH)₂D₃ (10 nmol/L) for 0, 6, 12, 24 h. The expression of CYP27A1 was determined by Western blot.
promotes the M2 polarization of macrophage-derived foam cells. In vitro stimulation with lipopolysaccharide demonstrated that macrophages from 1,25(OH)\textsubscript{2}D\textsubscript{3}-supplemented media produced significantly less proinflammatory cytokine, tumor necrosis factor-\(\alpha\), compared with macrophages from 1,25(OH)\textsubscript{2}D\textsubscript{3}-deficient media (Figure 4G). These results support the concept that 1,25(OH)\textsubscript{2}D\textsubscript{3} in macrophage is antiatherogenic via promotion of cholesterol efflux and anti-inflammatory macrophage polarization by upregulating LXR-\(\alpha\) pathway.

To clarify whether the regulated effect of 1,25(OH)\textsubscript{2}D\textsubscript{3} on macrophage is dependent on 27-HOC, we investigated the effect of 1,25(OH)\textsubscript{2}D\textsubscript{3} on CYP27A1 expression. CYP27A1 expression was controlled by activated JNK signal, as demonstrated in multiple cell types.20-22 After treatment with 1,25(OH)\textsubscript{2}D\textsubscript{3} for 30 minutes, the phosphorylation of JNK1/2 in THP-1 macrophage-derived foam cells was detected, and it was further enhanced \(\leq 3\) h (Figure 5A). We further used JNK signal inhibitor SP600125 to determine whether 1,25(OH)\textsubscript{2}D\textsubscript{3} is exerting its CYP27A1 induction effects through activated JNK signal. THP-1 macrophage-derived foam cells were treated with SP600125 for 30 minutes, followed by stimulation with 1,25(OH)\textsubscript{2}D\textsubscript{3} for 24 h. Total RNA were subjected to real-time PCR for CYP27A1, ATP-binding membrane cassette transporter A1 (ABCA1), and ATP-binding membrane cassette transporter G1 (ABCG1; \(\dagger\dagger\<0.01\) compared with untreated groups, \(\dagger\dagger\<0.01\) compared with 1,25(OH)\textsubscript{2}D\textsubscript{3} groups). The intercellular cholesterol efflux was determined by liquid scintillation counting. \(\dagger\dagger\<0.01\) compared with other groups. The data represent the mean±SE from 3 separate experiments with triplicate samples.

Figure 5. 1,25(OH)\textsubscript{2}D\textsubscript{3} induces CYP27A1 in a vitamin D receptor (VDR)–dependent c-Jun N-terminal kinase (JNK)/stress-activated protein kinase (SAPK) signal manner. A, Human monocytic cell line (THP-1) macrophage-derived foam cells were cultured with either 1,25(OH)\textsubscript{2}D\textsubscript{3} (10 nM) or vehicle at the indicated time point. Cells were harvested and subjected to Western blot analysis to monitor the levels of phosphorylation of JNK1/2. B, THP-1 macrophages were treated with 1,25(OH)\textsubscript{2}D\textsubscript{3} (10 nM) or JNK inhibitor SP600125 (2 \(\mu\)M) for 3 h. Total proteins were subjected to immunoblot analyses with antibody against p-JNK1/2. C, THP-1 macrophage-derived foam cells were treated with SP600125 (2 \(\mu\)M) for 30 minutes, followed by stimulation with 1,25(OH)\textsubscript{2}D\textsubscript{3} (10 nM) for 24 h. Total RNA were subjected to real-time PCR for CYP27A1, ATP-binding membrane cassette transporter A1 (ABCA1), and ATP-binding membrane cassette transporter G1 (ABCG1; \(\dagger\dagger\<0.01\) compared with untreated groups, \(\dagger\dagger\<0.01\) compared with 1,25(OH)\textsubscript{2}D\textsubscript{3} groups. D, THP-1 macrophage-derived foam cells were transfected with control or VDR siRNA for 48 h, and protein samples were immunoblotted with anti-VDR antibody. E, THP-1 macrophage-derived foam cells transfected with control (WT) or VDR siRNA (VDR\textsuperscript{−−}) were treated with 1,25(OH)\textsubscript{2}D\textsubscript{3} for 24 h. CYP27A1 was analyzed by Western blot. F, ABCA1, ABCG1, and liver X receptors (LXR)-\(\alpha\) expression were analyzed by Western blot. G, The intercellular cholesterol efflux was determined by liquid scintillation counting. \(\dagger\dagger\<0.01\) compared with other groups. The data represent the mean±SE from 3 separate experiments with triplicate samples.

1,25(OH)\textsubscript{2}D\textsubscript{3} Induces 27-Hydroxycholesterol in a VDR-Dependent JNK Signal Manner

CYP27A1 expression is controlled by activated JNK signal.20,21 In multiple cell types, the JNK pathway has been demonstrated to be activated by 1,25(OH)\textsubscript{2}D\textsubscript{3}.20-22 After treatment with 1,25(OH)\textsubscript{2}D\textsubscript{3} for 30 minutes, the phosphorylation of JNK1/2 in THP-1 macrophage-derived foam cells was detected, and it was further enhanced \(\leq 3\) h (Figure 5A). We further used JNK signal inhibitor SP600125 to determine whether 1,25(OH)\textsubscript{2}D\textsubscript{3} is exerting its CYP27A1 induction effects through activated JNK signal. THP-1 macrophage-derived foam cells were exposed to SP600125 or 1,25(OH)\textsubscript{2}D\textsubscript{3}. SP600125 almost completely blocked 1,25(OH)\textsubscript{2}D\textsubscript{3}-induced expression of phosphorylation of JNK1/2 in THP-1 macrophages (Figure 5B). The ability of 1,25(OH)\textsubscript{2}D\textsubscript{3} to induce CYP27A1, ABCA1, and ABCG1 mRNA expression in THP-1 macrophage-derived foam cells was significantly impaired by SP600125.
of vitamin D3 supplementation in modifying lipid profile and increased the level of HDL-C, suggesting the beneficial effect significantly prevented the development of atherosclerosis and of vitamin D3 in the diet (3000 IU per day×24 weeks) sig-
tor, under hypercholesterolemic condition. Supplementation plasma HDL-C level, a crucial cardiovascular protective fac-
ciency promoted the progress of atherosclerosis and decreased status on the progress of the disease. We found that VD defi-
dlevels that provide the direct evidence for the effect of VD with different VD diet, resulting in different plasma 25(OH)
siRNA (Figure 5D). The ability of 1,25(OH)2D3 to induce the expression of VDR was almost completely inhibited by we first incubated cells with 100 nmol/L VDR siRNA, and on CYP27A1 in THP-1 macrophage–derived foam cells,
expression is mediated by the JNK signaling pathway.
To test the role of VDR on the effect of 1,25(OH)D3 on CYP27A1 in THP-1 macrophage–derived foam cells, we first incubated cells with 100 nmol/L VDR siRNA, and the expression of VDR was almost completely inhibited by siRNA (Figure 5D). The ability of 1,25(OH)D3 to induce expression of CYP27A1 in THP-1 macrophage–derived foam cells was also significantly inhibited in VDR siRNA-treated cells (Figure 5E). We then confirmed a role of VDR in the 1,25(OH)2D3-mediated increase of cholesterol efflux in VDR knockdown cells. The effect of 1,25(OH)D3 on ABCA1, ABCG1, and LXR-α expression in VDR siRNA cells was significantly abolished compared with control siRNA-untreated cells (Figure 5F), indicating a VDR-dependent effects of 1,25(OH)D3 on LXR-α and its target genes. We further examined the role of VDR in the 1,25(OH)D3-induced cho-
sterol efflux using liquid scintillation counter. The ability of 1,25(OH)D3-induced cholesterol efflux in VDR siRNA cells was markedly decreased compared with that in control siRNA-treated cells (Figure 5G).

Discussion
Although clinical studies suggest that VD deficiency is related to a higher risk for cardiovascular disease, the exact role of VD in the progression of cardiovascular diseases has not been well defined. Because a higher plasma VD concentration is usu-
ally associated with a healthier lifestyle, it is unclear whether VD status is causally related to disease or is merely a marker of health. In this study, we fed hypercholesterolemic swine with different VD diet, resulting in different plasma 25(OH)D levels that provide the direct evidence for the effect of VD status on the progress of the disease. We found that VD deficiency promoted the progress of atherosclerosis and decreased plasma HDL-C level, a crucial cardiovascular protective factor, under hypercholesterolemic condition. Supplementation of vitamin D3 in the diet (3000 IU per day×24 weeks) sign-
ificantly prevented the development of atherosclerosis and increased the level of HDL-C, suggesting the beneficial effect of vitamin D3 supplementation in modifying lipid profile and decreasing cardiovascular disease. In a randomized clinical study, including 57 postmenopausal VD Def women, Catalano et al found that the supplementation with 25(OH)D3 (calcitriol) for 24 weeks significantly increased HDL-C level even after adjustment for age, baseline body mass index, 25(OH)D3, and lipid levels. In another randomized double-blind placebo-controlled clinical trial, including 70 participants with type 2 diabetes mellitus, it was found that the supplement-
mentation of calcitriol (1,25(OH)D3, 0.5 μg per day) for 12 weeks increased the HDL-C level compared with the placebo group. However, Ponda et al have reported no improvement in the lipid profile after short-term supplementation of vitamin D3 (50000 IU of vitamin D3 weekly for 8 Weeks) in VD Def adults with elevated risk for cardiovascular disease, suggesting that the dose and duration of treatment determine the out-
comes, and this remains to be elucidated.
Oxysterols are the endogenous ligands for the LXRs, ligand-activated transcription factors that can regulate a crucial checkpoint in cholesterol homeostasis. The sterol 27-hydroxylase (CYP27A1) is a mitochondrial cytochrome P450 and is involved in the synthesis of oxysterols, HOC, 3β-hydroxy-5-cholestenedic acid, and 25(OH)D3, which play a crucial role in cholesterol, bile acids, and VD metabolism. It was reported previously that vitamin D3 and its biologically active form, 1,25(OH)D3, can regulate expression of various CYP. Using a microarray method, we found that VD defi-
cency induces a response for the expression of the mRNA of genes associated with oxidative stress, lipid metabolism, and inflammation pathways in the liver. VD supplementation increased liver mRNA levels of oxidation–reduction and oxysterol-related CYP genes, including CYP1A1, CYP1A2, CYP2J34, and CYP27A1. In addition, we found that VD upregulates the expression of LXRα and ABCA1 in liver in a dose-dependent manner.
ABCA1 is a lipid transport protein transcriptionally regu-
lated by nuclear receptors LXR-α, which facilitates cellular cholesterol efflux to lipid-poor apoA-I and plays a key role in the formation and function of HDL. In mice, specific lack of ABCA1 in hepatocytes almost totally reduces the circulating HDL-C level. Mutations of ABCA1 in human underlie the
HDL deficiency syndrome, Tangier disease, suggesting that primarily hepatic ABCA1 determines the generation of nascent HDL particles.\(^{31,32}\) To clarify whether the regulated effect of VD on the HDL metabolism is related to the ABCA1 expression, we investigated the effect of 1,25(OH)\(_2\)D\(_3\) on the expression of ABCA1 and nascent HDL formation in hepatocytes and found that 1,25(OH)\(_2\)D\(_3\) promoted cellular cholesterol efflux to lipid-poor apoA-I, a major component of nascent HDL via upregulating ABCA1 expression. In several cholesterol-loaded cells, including hepatocytes and macrophages, LXR-\(\alpha\)/ABCA1 pathway has been found to be upregulated to promote the cholesterol efflux via a 27-HOC–dependent manner.\(^{33,34}\) In this study, we have shown for the first time that 1,25(OH)\(_2\)D\(_3\) facilitates the upregulation of LXR-\(\alpha\)/ABCA1 in cholesterol-loaded hepatocytes and macrophages via promoting the expression of CYP27A1. This effect could be supported by a recent clinical data, showing a significant positive correlation between the levels of 27-OHC and 25(OH)D\(_3\) under hypercholesterolemic condition.\(^{35}\) Interestingly, the LXR target genes, such as ABCG5/8, SREBP-1c, and SR-B1, were not found to be regulated by 1,25(OH)\(_2\)D\(_3\) in HepG2 cells (Figure II in the online-only Data Supplement). The conserved consensual cis-acting element DR4–dependent transcription is necessary for LXR-\(\alpha\)–induced ABCA1 expression in HepG2 cells.\(^{36}\) The activation of VDR by 1,25(OH)\(_2\)D\(_3\) has been found to recruit coactivators at DR4–type response element that leads to the expression of target genes.\(^{37,38}\) These results suggest that the recruitment of coactivators at the response element induced by 1,25(OH)\(_2\)D\(_3\) may be playing a critical role in supporting the transactivation of LXR-\(\alpha\)/ABCA1 pathway, though the exact mechanisms remain to be further examined.

Several studies have shown that 1,25(OH)\(_2\)D\(_3\) can regulate the differentiation, maturation, and function of macrophages,\(^{39,40}\) which prompted us to investigate whether the antiatherogenic effects of VD results from the direct effect of VD on the arterial wall. In this study, we found that VDR and CYP27B1, a key enzyme to control the synthesis of 1,25(OH)\(_2\)D\(_3\), are mainly expressed at the M2 macrophage foam cell–accumulated cores of plaques in the coronary artery. VD regulates the macrophage M1/M2 phenotype in diabetic nephropathy rats.\(^{36}\) In vitro, 1,25(OH)\(_2\)D\(_3\) has also been found to switch high glucose–induced M1/M2 polarization to suppress cholesteryl ester formation and to enhance cholesterol efflux in M2 macrophages.\(^{41,42}\) In atherosclerotic lesion, we found that VDR is primarily coexpressed with ABCA1/ABCG1 at M2 macrophage–derived foam cell. In vitro, 1,25(OH)\(_2\)D\(_3\) has been found to promote the cholesterol efflux and polarize macrophages to proinflammatory M2 phenotype. In macrophages, ABCA1 and ABCG1, another ABC family of transporter, play critical role in mobilizing cholesterol out of macrophages and onto extracellular HDL.\(^{43}\) In addition to its lipid transport function, ABCA1 and ABCG1 have been found to play a crucial role in the regulation of cytokine-triggered macrophage polarization programs and inflammatory response.\(^{44,45}\) Several studies have shown that the cholesterol export activity of ABCA1/ABCG1 could account for its potent anti-inflammatory properties.\(^{46,47}\) Knockdown of ABCA1 in macrophage results in an increase of cell membrane cholesterol and lipid raft content, which facilitate toll-like receptor 4-MyD88-mediated proinflammatory response.\(^{48}\) In this study, we found that 1,25(OH)\(_2\)D\(_3\) markedly induced the expression of ABCA1 and ABCG1 in macrophages, suggesting that enhanced cholesterol efflux may play a crucial role in anti-inflammatory effect of VD.

Previously, JNK/c-jun pathway has been reported to upregulate the expression of CYP27A1 in hepatocytes.\(^{20}\) 1,25(OH)\(_2\)D\(_3\) activates the JNK/c-jun pathway in various cell lines.\(^{21,22,49}\) Consistently, our study demonstrated that 1,25(OH)\(_2\)D\(_3\) upregulates the phosphorylation of JNK in macrophages. Furthermore, inhibitor of JNK activation blocks 1,25(OH)\(_2\)D\(_3\)–induced upregulation of CYP27A1 and 27-HOC content, suggesting that JNK/c-Jun activation plays an important role in antiatherogenic activity of VD. Both VDR and LXR-\(\alpha\) are crucial lipid-activated nuclear receptors that shape macrophage function.\(^{30}\) Earlier studies have shown that VDR is regulated by LXR-\(\alpha\) through its ability to modulate sterol regulatory element–binding protein present in the promoter region of VDR gene.\(^{35}\) In our study, we found that LXR-\(\alpha\) pathway is also regulated by VDR through its ability to modulate CYP27A1 and 27-HOC (Figure 6), suggesting the existence of crosstalk between LXR and VDR that stimulates the intracellular pathway to exert the antiatherogenic effect.

In conclusion, the findings in this study revealed a novel mechanistic link between VD deficiency and cardiovascular risk. VD supplementation significantly increased the levels of plasma HDL and the expression of 27-HOC/LXR-\(\alpha\) pathway, which contributes to alleviate cholesterol toxicity and macrophage proinflammatory polarization, resulting in protection against the development of atherosclerosis.

Sources of Funding
This work was supported by research grants HL112597, HL116042, and HL120659 from the National Institutes of Health, USA, to D.K. Agrawal. K. Yin is supported, in part, by the research grants 81100213 and 81470569 from National Natural Science Foundation of China (NSFC).

Disclosures
The content of this research article is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health and National Natural Science Foundation of China. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the article apart from those disclosed. No writing assistance was used in the production of this article.

References
1. Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell. 2011;145:341–355. doi: 10.1016/j.cell.2011.04.005.
2. Sene A, Khan AA, Cox D, et al. Impaired cholesterol efflux in senescent macrophages promotes age-related macular degeneration. Cell Metab. 2013;17:549–561. doi: 10.1016/j.cmet.2013.03.009.
3. Das R, Gunapathy S, Mahabaleshwar GH, Drumm C, Febbraio M, Jain MK, Plow EF. Macrophage gene expression and foam cell formation are regulated by plasminogen. Circulation. 2013;127:1209–1218, e1. doi: 10.1161/CIRCULATIONAHA.112.001214.
4. Colin S, Chinetti-Gbaguidi G, Staels B. Macrophage phenotypes in atherosclerosis. Immunol Rev. 2014;262:153–166. doi: 10.1111/imr.12218.
5. Leitinger N, Schultz IG. Phenotypic polarization of macrophages in atherosclerosis. Arterioscler Thromb Vasc Biol. 2013;33:1120–1126. doi: 10.1161/ATVBAHA.112.300173.
6. Holick MF. Vitamin D deficiency. *N Engl J Med.* 2007;357:266–281. doi: 10.1056/NEJMra070553.

7. Yin K, Agrawal DK. Vitamin D and inflammatory diseases. *J Inflamm Res.* 2014;7:69–87. doi: 10.2147/JIR.S63989.

8. Kassi E, Adamopoulos C, Basdra EK, Papavasiliou AG. Role of vitamin D in atherosclerosis. *Circulation.* 2013;128:2517–2521. doi: 10.1161/CIRCULATIONAHA.113.002654.

9. Kim DH, Sabour S, Sagar UN, Adams S, Thewiss J, Khademian A, Levine B, Mehrrota R, Norris K. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. *Arch Intern Med.* 2007;167:1159–1165. doi: 10.1001/archinte.167.11.1159.

10. Vitezova A, Zilkennis MC, van Herpt TT, Sijbrands EJ, Hofman A, Ocke MC, Preedy VR. Skeletal muscle and liver oxysterols during fasting and alcohol exposure. *Obes Metab.* 2005.08.003.

11. van Eck M. ATP-binding cassette transporter A1: key player in cardiovascular and metabolic disease at local and systemic level. *Curr Opin Lipidol.* 2014;25:297–303. doi: 10.1097/MOL.0000000000000088.

12. Vitezova A, Zilkennis MC, van Herpt TT, Sijbrands EJ, Hofman A, Ocke MC, Preedy VR. Skeletal muscle and liver oxysterols during fasting and alcohol exposure. *Obes Metab.* 2005.08.003.

13. Haara A, Schnedl W, Gerads M, McDonell DP. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. *Science.* 2013;342:1094–1098. doi: 10.1126/science.1240671.

14. Haara A, Schnedl W, Gerads M, McDonell DP. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. *Science.* 2013;342:1094–1098. doi: 10.1126/science.1240671.

15. Jones G, Gross DE, Kaufmann M, Cytochrome P450-mediated metabolism of Vitamin D. *J Lipid Res.* 2014;55:13–31. doi: 10.1194/jlr.R031534.

16. Jones G, Gross DE, Kaufmann M, Cytochrome P450-mediated metabolism of Vitamin D. *J Lipid Res.* 2014;55:13–31. doi: 10.1194/jlr.R031534.

17. Kim Y, Liao DF, Tang CK. ATP-binding membrane transporter A1 (ABCA1): a possible link between inflammation and reverse cholesterol transport. *Mol Med.* 2010;16:438–449. doi: 10.2119/molmed.2010.00004.

18. Kim Y, Liao DF, Tang CK. ATP-binding membrane transporter A1 (ABCA1): a possible link between inflammation and reverse cholesterol transport. *Mol Med.* 2010;16:438–449. doi: 10.2119/molmed.2010.00004.
hallmarks tissue macrophages and modulates cytokine-triggered polarization programs. *Eur J Immunol*. 2009;39:2270–2280. doi: 10.1002/eji.200838867.

46. Westerterp M, Bochem AE, Yvan-Charvet L, Murphy AJ, Wang N, Tall AR. ATP-binding cassette transporters, atherosclerosis, and inflammation. *Circ Res*. 2014;114:157–170. doi: 10.1161/CIRCRESAHA.114.300738.

47. Westerterp M, Murphy AJ, Wang M, et al. Deficiency of ATP-binding cassette transporters A1 and G1 in macrophages increases inflammation and accelerates atherosclerosis in mice. *Circ Res*. 2013;112:1456–1465. doi: 10.1161/CIRCRESAHA.113.301086.

48. Zhu X, Owen JS, Wilson MD, Li H, Griffiths GL, Thomas MJ, Hiltbold EM, Fessler MB, Parks JS. Macrophage ABCA1 reduces MyD88-dependent Toll-like receptor trafficking to lipid rafts by reduction of lipid raft cholesterol. *J Lipid Res*. 2010;51:3196–3206. doi: 10.1194/jlr.M006486.

49. Buitrago CG, Ronda AC, de Boland AR, Boland R. MAP kinases p38 and JNK are activated by the steroid hormone 1alpha,25(OH)2-vitamin D3 in the C2C12 muscle cell line. *J Cell Biochem*. 2006;97:698–708. doi: 10.1002/jcb.20639.

50. Kiss M, Czimmerer Z, Nagy L. The role of lipid-activated nuclear receptors in shaping macrophage and dendritic cell function: From physiology to pathology. *J Allergy Clin Immunol*. 2013;132:264–286. doi: 10.1016/j.jaci.2013.05.044.

51. Dave VP, Kaul D, Sharma M. Crosstalk between RXR, LXR and VDR within blood mononuclear cellular model. *Indian J Exp Biol*. 2012;50:35–40.

**Significance**

Epidemiological studies suggest that vitamin D deficiency is related to a proatherogenic lipid profile and inflammation. However, the exact role of vitamin D in the progress of atherosclerosis has not been fully elucidated. Here, we found that vitamin D deficiency accelerated the development of atherosclerosis in hypercholesterolemic swine, which is similar to the lipid metabolism and the progress of atherosclerosis in human. Vitamin D deficiency results in impaired cholesterol efflux in the liver and artery that leads to decreased high-density lipoprotein level, cholesterol accumulation, and M1 macrophage polarization in vascular wall. The 1,25(OH)2D3 markedly induced CYP27A1 expression and increased 27-hydroxycholesterol levels, which induced cholesterol efflux. These results suggest that vitamin D supplementation might serve as a novel therapeutic modality to increase high-density lipoprotein level and decrease severity of atherosclerosis in patients with cardiovascular disease risk.